TITLE

Big Pharma's Mid-Market Influence

AUTHOR(S)
Marino, Jonathan
PUB. DATE
May 2009
SOURCE
Mergers & Acquisitions Report;5/4/2009, Vol. 22 Issue 18, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the impact of three mergers worth a combined 156 billion U.S. dollars on the deal market in the pharmaceutical industry. Wyeth was acquired by Pfizer for 68 billion U.S. dollars, while Schering-Plough was acquired by Merck for 41.1 billion U.S. dollars. It is noted that mid-market dealmakers are optimistic that the mergers will result in opportunities in the smaller deal realm.
ACCESSION #
44127823

 

Related Articles

  • Top 10 pharma firings of 2009.  // Nature Medicine;Jan2010, Vol. 16 Issue 1, p6 

    The article focuses on the 2009 condition of pharmaceutical industry in the U.S. According to consulting firm Challenger Gray & Christmas Inc., 61,109 pharma and biotech jobs were cut through the end of November 2009. It notes that Pfizer Inc. is the most successful among the pharmaceutical...

  • News Briefs.  // American Journal of Health-System Pharmacy;12/15/2009, Vol. 66 Issue 24, p2161 

    The article offers news briefs related to business activities. The website ResearchMatch.org was launched by a national network of medical research groups with the help of a federal fund on November 10, 2009 to provide research studies to enhance the health and well-being of the people. The...

  • Big Pharma, big dealing. Galloro, Vince // Modern Healthcare;7/27/2009, Vol. 39 Issue 30, p0014 

    This article reports on the move by Bristol-Myers Squibb Co. to offer bid to acquire Medarex, a biologics drugmaker based in Princeton, New Jersey. The New York-based Bristol-Myers offered 2.1 billion U.S. dollars for Medarex with which it has had a partnership since 2005. Meanwhile, shareholdes...

  • Big Pharma's Mid-Market Influence. Marino, Jonathan // High Yield Report;5/11/2009, Vol. 20 Issue 19, p7 

    The article reports on the implications of the merger activity among large pharmaceutical companies in 2009. These deals include Pfizer's acquisition of Wyeth for 68 billion U.S. dollars, Merck's purchase of Schering-Plough for 41.1 billion U.S. dollars and Roche's win to takeover Genentech....

  • Rx mergers on the rise. DeArment, Alaric // Drug Store News;4/20/2009, Vol. 31 Issue 5, p96 

    The article offers information on the prevalence of the merging of pharmaceutical companies in New York. In January 2009, Pfizer is rumoured to purchase Wyeth worth $38 billion. In March 2009, Merck & Co. announces its plan to buy Schering-Plough Corp. for $41.1 billion while Roche unveiled its...

  • GLOBAL CONSOLIDATION MANIA.  // Finweek;5/14/2009, p25 

    The article focuses on the major consolidation deals in the international pharmaceutical and biotechnology industry in 2009. According to the article, the consolidation in the sector depicts its rapid continuation despite the credit crisis. It cites that the biggest deal is the sale of Wyeth to...

  • Big Pharma's Mid-Market Influence. Marino, Jonathan // Mergers & Acquisitions: The Dealermaker's Journal;May2009, Vol. 44 Issue 5, p20 

    The article discusses the influence of big pharma companies on mergers and acquisitions (M&A) market. Pfizer Inc. acquired the firm Wyeth for $68 billion, Merck & Co. Inc. acquired Schering-Plough Corp. for $41.1 billion and Hoffmann-La Roche Inc. won its bid to takeover Genentech Inc. in a $47...

  • Vacancies could surge as pharma firms merge. LEE, EVELYN // njbiz;10/12/2009, Vol. 22 Issue 41, p1 

    The article reports that Pfizer and Wyeth, and Merck and Schering-Plough will merge in the fourth quarter of 2009. While New Jersey's real estate industry is getting ready for mergers that will position large blocks of space in the market, insiders expect growth from small pharmaceutical firms...

  • Big Pharma Tightens Its Global Manufacturing Belt. Van Arnum, Patricia // Pharmaceutical Technology;Dec2009 Corporate Capabilities Supp, p49 

    The article discusses the restructuring and cost-saving efforts of large pharmaceutical companies in the face of consolidation and shifting manufacturing priorities around the industry. It highlights the deals between large pharmaceutical companies including Pfizer Inc.'s acquisition of Wyeth,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics